Key Developments: Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

6:18am EDT
Price Change (% chg)

Rs6.10 (+1.39%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Cipla Ltd's MSPL acquires Mabpharm
Thursday, 17 Jul 2014 06:57am EDT 

Cipla Ltd:Says a subsidiary Meditab Specialities Pvt Ltd (MSPL), has acquired 75 pct stake in Mabpharm Pvt Ltd(Mabpharm).The company was earlier holding 25 pct stake in Mabpharm.Consequent to the acquisition of the aforesaid stake, Mabpharm has now become 100 pct subsidiary of the company.Mabpharm is inter alia engaged in development of monoclonal anitbodies for treatment of cancer and auto-immune diseases.Financial terms of the acquisition were not disclosed.  Full Article

Cipla Ltd signs definitive agreement to acquire 51 pct. stake in pharmaceuticals manufacturing and distribution business in Yemen
Sunday, 29 Jun 2014 11:35pm EDT 

Cipla Ltd:Signs definitive agreement to acquire 51 pct. stake in a pharmaceuticals manufacturing and distribution business in Yemen (in turn owned by a UAE based parent company).Says it will pay $21 mln for this transaction, with additional considerations to be paid over next three years on achievement of agreed milestones.Closing of transaction is subject to completion of certain conditions precedent.  Full Article

Cipla Ltd updates on subsidiary company
Tuesday, 17 Jun 2014 04:28am EDT 

Cipla Ltd:Cipla (mauritius) Limited, wholly owned subsidiary of the company has signed definitive agreement with the company’s existing Sri Lankan distributor for acquisition of 60 pct stake in new company which will market the Company’s products in Sri Lanka.Consideration payable for the transaction is $14 mln.  Full Article

Cipla Ltd recommends payment of dividend
Thursday, 29 May 2014 08:50am EDT 

Cipla Ltd:Recommends payment of dividend of 2 Indian rupees per equity share (face value 2 rupees per equity share) for the year 2013-2014 amounting to 1.6058 bln rupees.Dividend, subject to the approval of shareholders, will be dispatched / credited on or after Aug. 27, 2014.  Full Article

Cipla Ltd's Meditab Holdings Ltd Announces Acquisition Of Additional 14.5% Stake In Quality Chemical Industries Ltd
Thursday, 21 Nov 2013 02:56am EST 

Cipla Ltd announced that Meditab Holdings Limited (MHL), a wholly owned step down subsidiary of the Company, has acquired an additional 14.5% stake in Quality Chemical Industries Limited (QCIL), Uganda for a consideration of USD 15 million. QCIL’s principal activity is manufacturing and selling of pharmaceutical drugs with emphasis on anti-retroviral (ARV’s) and anti-malarial drugs. QCIL has a WHO approved manufacturing facility in Uganda. MHL was earlier holding 36.55% stake in QCIL. Consequent to the acquisition of aforesaid additional stake, MHL now holds 51.05% stake in QCIL.  Full Article

Cipla Ltd Completes Acquisition Of Cipla Medpro South Africa Limited
Tuesday, 16 Jul 2013 04:34am EDT 

Cipla Ltd announced that with reference to the earlier announcement in regards to the proposed acquisition of 100% of the issued shares of Medpro by the Company (Scheme) and subsequent updates in relation to various approvals received in relation to the Scheme, Cipla Ltd has informed that the Company have completed the acquisition of 100% of the issued shares of Medpro and the listing of the shares of Medpro on the JSE Limited has been terminated from the commencement of business on July 16, 2013.  Full Article

Cipla Medpro South Africa Ltd Updates On Scheme Of Arrangement With Cipla Limited
Friday, 28 Jun 2013 03:12am EDT 

Cipla Medpro South Africa Ltd announced that with reference to the previous announcement, regarding the approval at the general meeting of Cipla Medpro, by the requisite majority of shareholder votes, of the scheme of arrangement proposed by the board of directors of Cipla Medpro between Cipla Medpro and shareholders, in respect of the acquisition by Cipla India of 100% of the issued ordinary shares of Cipla Medpro (the Scheme). Shareholders are hereby advised that all conditions precedent to the Scheme, as detailed in the Circular issued to Cipla Medpro shareholders on April 15, 2013 (the Circular), have been fulfilled or waived (a TRP compliance certificate having been received on June 27, 2013), and accordingly, the Scheme has become unconditional, as of June 27, 2013. In terms of the Scheme, each Cipla Medpro shareholder is entitled to receive a cash consideration of ZAR10.00 for every Cipla Medpro share held.  Full Article

Cipla Ltd Updates On 100% of Cipla Medpro South Africa Ltd
Thursday, 20 Jun 2013 06:34am EDT 

Cipla Ltd updated on the acquisition of 100% of Cipla Medpro South Africa Limited shares that the approvals for the Scheme from the South African and Botswana competition authorities have been received.  Full Article

Meda AB Expands Collaboration With Indian Pharmaceutical Company Cipla Ltd
Wednesday, 5 Jun 2013 07:20am EDT 

Meda AB announced that it is broadening collaboration with the Indian pharmaceutical company Cipla, thereby expanding exclusive rights to Dymista and future product development. Through the extended partnership, Meda now have full coverage in all growth markets in Latin- and South America, Middle East and Africa and Asia, including more than 120 new markets. Meda and Cipla will cooperate on product development of Dymista. Cipla will be responsible for formulation, while Meda will be responsible for clinical development, registration, marketing and sales. The companies will also collaborate on future production of Dymista and any new products developed.  Full Article

Cipla Ltd Fixes Book Closure For Dividend
Wednesday, 29 May 2013 10:25pm EDT 

Cipla Ltd announced that the Register of Members & Share Transfer Books of the Company will remain closed from August 08, 2013 to August 22, 2013 (both days inclusive) for the purpose of Payment of Dividend & Annual General Meeting (AGM) of the Company. The Dividend, subject to the approval of shareholders, will be dispatched/credited on or after August 27, 2013.  Full Article

UPDATE 1-S.African govt awards $33 mln respiratory contract to Cipla

CAPE TOWN, June 26 - South Africa has awarded Cipla Medpro a 345 million rand ($32.6 million) share in the national respiratory tender as Africa's most advanced economy seeks to cut high asthma mortality rates, the company said on Thursday.

Search Stocks